Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto K, Kikuta A, Nishiyama Y, Kojima S, Matsuyama T, Morishima T
Department of Pediatrics, Research Institute for Disease Mechanism and Control, Nagoya University School of Medicine, Japan.
Bone Marrow Transplant. 2000 Jul;26(2):199-201. doi: 10.1038/sj.bmt.1702492.
Using a real-time quantitative PCR assay, we identified two patients with EBV-related lymphoproliferative disorders at a very early stage. Both had received an unmanipulated bone marrow transplant with anti-thymocyte globulin for conditioning. To estimate virus-specific immunity, the frequencies of EBV-specific CD8+ T cells were measured using an enzyme-linked immunospot assay. The frequencies of EBV-specific CD8+ T cells of the two were 3.2 and 7.7%, respectively, which had possibly expanded in vivo. After withdrawing the immunosuppressive agents or administering donor lymphocytes transfusion, their symptoms regressed in parallel with the viral load.
通过实时定量聚合酶链反应检测,我们在非常早期阶段就识别出两名患有EB病毒相关淋巴增殖性疾病的患者。两人均接受了使用抗胸腺细胞球蛋白进行预处理的未处理骨髓移植。为了评估病毒特异性免疫,使用酶联免疫斑点试验测量EB病毒特异性CD8+T细胞的频率。两人的EB病毒特异性CD8+T细胞频率分别为3.2%和7.7%,这些细胞可能在体内已经扩增。在停用免疫抑制剂或进行供体淋巴细胞输注后,他们的症状随着病毒载量的下降而消退。